carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['durva', 'duo-o']
duo-o results not exactly impressive. study designed so as to lead to positive primary endpoint. durvalumab addition provides no effect. #asco23 
Ασυνάρτητος και ημιτελής. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.